355 Results
Sort By:
Published on September 24, 2018
Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. Researchers from Epic and Memorial Sloan…
Published on July 17, 2018
The NIH and the Prostate Cancer Foundation (PCF) said today they have launched a study designed to investigate environmental and genetic factors related to aggressiveness of prostate cancer in African-American men, to better enable personalized treatments. The $26.5 million RESPOND study (for Research on Prostate Cancer in Men of African…
Published on June 14, 2018
Researchers in the U.S. and U.K. have identified a new subtype of prostate cancer that is characterized by loss of both copies of the CDK12 gene, and which an early clinical study showed can respond to immune checkpoint inhibitor drugs that commonly aren’t effective against prostate cancer. The new tumor…
Published on June 11, 2018
New testing strategies for prostate cancer, including noninvasive saliva tests, may be close to hand, now that an in-depth study of DNA samples from more than 140,000 men has implicated 63 additional genetic variants of prostate cancer risk. By adding the newfound variants to previously known prostate cancer risk variants,…
Published on May 9, 2018
Protagen said today that its SeroTag immune-system profiling technology will be used by University of California, San Francisco (UCSF) researchers to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors and therapeutic vaccines. The value of the collaboration was not disclosed. Through the collaboration, Protagen said, its investigators and…
Published on May 8, 2018
GenomeDx Biosciences said today it will use its Decipher Prostate Cancer Classifier tests, and the database from which they are derived, to test samples from multiple clinical trials by Johnson & Johnson’s Janssen Pharmaceuticals in order to assess prostate cancer candidates. The companies plan to examine the association of prognostic…
Published on March 30, 2018
The nation’s largest Medicare administrative contractor, Palmetto GBA, has issued a draft local coverage determination (LCD) recommending Medicare coverage for the Oncotype DX AR-V7 Nucleus Detect, the companies co-marketing the liquid biopsy test said today. Epic Sciences and Genomic Health noted that the draft LCD recommends Medicare coverage for use…
Published on March 6, 2018
The American Association of Clinical Urologists (AACU) has issued a position statement encouraging the use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients. The Association, which represents nearly 4,000 member urologists nationwide, said in the one-page statement that tissue-based molecular testing “should be considered”…
Published on February 27, 2018
The Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute have launched the Metastatic Prostate Cancer (MPC) Project, designed to encourage men with metastatic prostate cancer in the U.S. and Canada to share their data with researchers studying the disease. As of yesterday, when MPC was announced, 220…
Published on January 17, 2018
Researchers at the Cleveland Clinic, led by Nima Sharifi, M.D., have identified a mechanistic link between a specific gene and treatment-resistant prostate cancer. In the research, detailed in the journal Cell Reports, Sharifi and his team show that men who lack a certain subtype of the gene HSD17B4 may be…
Published on December 6, 2017
Genomic Health said today its Oncotype DX Genomic Prostate Score (GPS) test will be evaluated for the prostate cancer drug pipeline of Johnson & Johnson’s Janssen Pharmaceuticals through a research collaboration whose value was not disclosed. Under the collaboration, Genomic Health has agreed to test samples from Janssen studies while…
Published on December 5, 2017
Precision cancer therapy developer Perthera is partnering with ZERO, the prostate cancer research advocacy and patient support group, to launch a pilot nationwide molecular profiling program designed to identify treatment options for men with the disease. Through their Decode Your Prostate Cancer program, ZERO and Perthera said they will enable…
Published on November 29, 2017
Genomic Health will develop and commercialize new prostate cancer tests based on the IsoPSA™ reagents and technology of Cleveland Diagnostics, through a $10 million-plus collaboration disclosed by the companies. Under an exclusive licensing agreement, initial efforts will focus on Genomic Health's development of a high- prostate-specific antigen (PSA) reflex test…
Published on October 3, 2017
Strata Oncology said today it will partner with University of California, San Francisco (UCSF), to expand access to tumor sequencing and clinical trials for men with metastatic prostate cancer. Strata, a precision oncology company, and UCSF are launching Stratify Prostate™, an initiative aimed at advancing precision medicine among men with…
Published on February 1, 2017
GenomeDx said today that its Decipher Classifier tests and Decipher Genomics Resource Information Database (GRID) will be used by Astellas to identify active-surveillance prostate cancer patients who may benefit from Xtandi (enzalutamide), the drug it co-markets with Medivation. The value of the collaboration was not disclosed. Astellas has agreed to…